Paciullo Francesco, Giannandrea David, Virgili Gianni, Cagini Carlo, Gresele Paolo
Division of Internal and Cardiovascular Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Division of Neurology and Stroke Unit, Department of Neurology, Gubbio and Città di Castello Hospital, Perugia, Italy.
TH Open. 2021 Jul 6;5(3):e295-e302. doi: 10.1055/s-0041-1732803. eCollection 2021 Jul.
Increased lipoprotein (a) [Lp(a)] has been associated with enhanced risk of cardiovascular events and more recently with venous thromboembolism. However, there is inconclusive data on the association between enhanced Lp(a) and retinal vein occlusion (RVO). We aimed to assess the role of Lp(a) in RVO. We performed a systematic review and meta-analysis of the studies addressing the role of Lp(a) in RVO. A systematic literature search was performed to identify all published papers reporting Lp(a) levels. Main outcome measures consisted of Lp(a) levels in patients with (cases) or without (controls) RVO. We included 13 studies for a total of 1,040 cases and 16,648 controls. Lp(a) levels above normal limits were associated with RVO (OR 2.38, 95% CI 1.7-3.34) and patients with RVO had higher Lp(a) levels than controls (weighted mean difference: 13.4 mg/dL, 95% CI 8.2-18.6). Increased Lp(a) levels associate with RVO and should be included among diagnostic and prognostic indexes for this unusual-site vein thrombosis. Therapeutic interventions aimed to lower Lp(a) should be tested in RVO patients.
脂蛋白（a）[Lp（a）]水平升高与心血管事件风险增加相关，最近还与静脉血栓栓塞有关。然而，关于Lp（a）水平升高与视网膜静脉阻塞（RVO）之间的关联，数据尚无定论。我们旨在评估Lp（a）在RVO中的作用。
我们对探讨Lp（a）在RVO中作用的研究进行了系统评价和荟萃分析。进行了系统的文献检索，以确定所有报告Lp（a）水平的已发表论文。主要观察指标包括患有（病例组）或未患有（对照组）RVO患者的Lp（a）水平。
我们纳入了13项研究，共计1040例病例和16648例对照。Lp（a）水平高于正常范围与RVO相关（比值比2.38，95%置信区间1.7 - 3.34），且RVO患者的Lp（a）水平高于对照组（加权平均差：13.4mg/dL，95%置信区间8.2 - 18.6）。
Lp（a）水平升高与RVO相关，应纳入这种罕见部位静脉血栓形成的诊断和预后指标中。旨在降低Lp（a）的治疗干预措施应在RVO患者中进行试验。
